Actively Recruiting
A Phase 1 Study of ADI-001 in Rheumatoid Arthritis
Led by Adicet Therapeutics · Updated on 2025-12-08
25
Participants Needed
1
Research Sites
128 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
ADI-001-106 is a phase 1 study of ADI-001 with a randomized, single-blind, parallel group design to compare two different LD regimens in subjects with treatment-refractory RA. The study will consist of different periods including screening, LD, treatment, and follow-up
CONDITIONS
Official Title
A Phase 1 Study of ADI-001 in Rheumatoid Arthritis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Diagnosed with rheumatoid arthritis meeting the 2010 ACR-EULAR classification criteria
- Agree not to take traditional medicines or medications not prescribed by a doctor
- Adequate blood, liver, heart, and lung function
You will not qualify if you...
- Severe liver disease classified as Child-Pugh class B or C
- Autoimmune disease requiring prednisone higher than 0.5 mg/kg/day or corticosteroid equivalent
- Unwillingness to participate in an extended safety monitoring period
- History of a significant infection within 4 weeks prior to first study drug dose that may compromise safety
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Adicet Clinical Trials
Shanghai, Shanghai Municipality, China
Actively Recruiting
Research Team
A
Adicet Medical Monitor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
5
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here